Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

-
June 2, 2020
Chundsell Medicals AB

Covid 19 - Prostate type would help healthcare prioritize prostate cancer patients who really need radical treatment

Covid 19 - Prostate type would help healthcare prioritize prostate cancer patients who really need radical treatment

-
Chundsell Medicals AB
-
June 2, 2020

The ongoing Corona pandemic explains, for obvious reasons, that the recommendations contained in the national prostate cancer care program cannot be followed. The treatment of people with suspected or known prostate cancer is affected by the great need for care for those who have been infected with coronaviruses, and by reduced healthcare resources due to sick leave. The National Health Care Program Group recommends that PSA test men who have no symptoms or research findings that prompt suspicion of prostate cancer. Operators must also identify which patient groups can be managed according to the care program and which should have their care adapted to the prevailing conditions during the pandemic.1

Categorizing patients into the right risk group is always important, but is even more important under prevailing circumstances. The prognostic gene test Prostatype can help care to prioritize the right patients, so that those who really need radical treatment get it. Urologist Michael Häggman, chief physician at Uppsala Academic Hospital comments on the situation:

-Setting the right prognosis for prostate cancer patients is a challenge even under normal circumstances, but is becoming even more important during this time as the consequences can be devastating for the individual patient. Being able to determine with greater certainty which patients really have an aggressive cancer that requires radical treatment would undoubtedly affect the course of events.

In recent years there have been tests that can complement today's clinical tools to better identify men who do not risk having prostate cancer requiring treatment. One such test is Prostatype, which by means of a gene test using cells from already taken tissue samples gives a measure of how aggressive the prostate cancer is. It provides a better basis for the vital decision on treatment. The prostate type was developed by Chundsell Medicals AB and is the result of many years of research at Karolinska Institutet.

- Radical treatment saves lives if the patients who really need care get it when they need it. If the wait becomes too long, it may be too late. The prostate type shows how aggressive a prostate cancer is and helps the healthcare provider better choose the patients who really need treatment or not. While the pressure on the care queues can be reduced, the over-treatment of prostate cancer patients is also reduced. In other words, Prostatype fills the gap that exists when the test helps patients, doctors and healthcare to make a more informative decision with higher quality for all parties involved, says Fredrik Persson, CEO of Chundsell Medicals AB.

For more information, please contact Fredrik Persson, CEO of Chundsell Medicals AB, fredrik.persson@chundsell.com, 073 049 77 01.

Prostate type is a gene test that is available to patients and treating urologists as a supplementary decision basis for the treatment or not treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Chundsell Medicals AB.

https://www.cancercentrum.se/globalassets/covid-19/prostata_avvikelse_24apr20.pdf

The post Covid 19 - Prostate Type would help healthcare prioritize prostate cancer patients who really need radical treatment appeared first on Chundsell.

Last updated:
June 2, 2020

Chundsell Medicals AB

The company Chundsell Medicals AB was founded in 2007 as a spin off from Cancer Center Karolinska (Karolinska Institutet, Stockholm, Sweden) in order to transfer the research results of Dr. Chunde Li and his group into clinical reality.

Click here to read more about us!
Get in touch with us!
Visit us
Send us mail

The ongoing Corona pandemic explains, for obvious reasons, that the recommendations contained in the national prostate cancer care program cannot be followed. The treatment of people with suspected or known prostate cancer is affected by the great need for care for those who have been infected with coronaviruses, and by reduced healthcare resources due to sick leave. The National Health Care Program Group recommends that PSA test men who have no symptoms or research findings that prompt suspicion of prostate cancer. Operators must also identify which patient groups can be managed according to the care program and which should have their care adapted to the prevailing conditions during the pandemic.1

Categorizing patients into the right risk group is always important, but is even more important under prevailing circumstances. The prognostic gene test Prostatype can help care to prioritize the right patients, so that those who really need radical treatment get it. Urologist Michael Häggman, chief physician at Uppsala Academic Hospital comments on the situation:

-Setting the right prognosis for prostate cancer patients is a challenge even under normal circumstances, but is becoming even more important during this time as the consequences can be devastating for the individual patient. Being able to determine with greater certainty which patients really have an aggressive cancer that requires radical treatment would undoubtedly affect the course of events.

In recent years there have been tests that can complement today's clinical tools to better identify men who do not risk having prostate cancer requiring treatment. One such test is Prostatype, which by means of a gene test using cells from already taken tissue samples gives a measure of how aggressive the prostate cancer is. It provides a better basis for the vital decision on treatment. The prostate type was developed by Chundsell Medicals AB and is the result of many years of research at Karolinska Institutet.

- Radical treatment saves lives if the patients who really need care get it when they need it. If the wait becomes too long, it may be too late. The prostate type shows how aggressive a prostate cancer is and helps the healthcare provider better choose the patients who really need treatment or not. While the pressure on the care queues can be reduced, the over-treatment of prostate cancer patients is also reduced. In other words, Prostatype fills the gap that exists when the test helps patients, doctors and healthcare to make a more informative decision with higher quality for all parties involved, says Fredrik Persson, CEO of Chundsell Medicals AB.

For more information, please contact Fredrik Persson, CEO of Chundsell Medicals AB, fredrik.persson@chundsell.com, 073 049 77 01.

Prostate type is a gene test that is available to patients and treating urologists as a supplementary decision basis for the treatment or not treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Chundsell Medicals AB.

https://www.cancercentrum.se/globalassets/covid-19/prostata_avvikelse_24apr20.pdf

The post Covid 19 - Prostate Type would help healthcare prioritize prostate cancer patients who really need radical treatment appeared first on Chundsell.

Last updated:
June 2, 2020

Chundsell Medicals AB

The company Chundsell Medicals AB was founded in 2007 as a spin off from Cancer Center Karolinska (Karolinska Institutet, Stockholm, Sweden) in order to transfer the research results of Dr. Chunde Li and his group into clinical reality.

Click here to read more about us!
Get in touch with us!
Visit us
Send us mail